Abstract
Orteronel (TAK-700) is a novel and selective inhibitor of CYP17A1, which is expressed in testicular, adrenal and prostate tumor tissues. Orteronel is currently in Phase-III clinical development for metastatic castration-resistant prostate patients. The objective of the study is to assess the permeability, metabolic stability (in various preclinical and human liver microsomes), identify the major CYPs involved in the metabolism of Orteronel. We have also studied the pharmacokinetics and excretion of Orteronel in Sprague–Dawley rats. Orteronel was found to be stable in various liver microsomes tested. The half-life (t ½) of Orteronel with intravenous (i.v.) route was found to be 1.65 ± 0.22 h. The clearance and volume of distribution by i.v. route for Orteronel were found to be 27.5 ± 3.09 mL/min/kg and 3.94 ± 0.85 L/kg, respectively. The absorption of Orteronel was rapid, with maximum concentrations of drug in plasma of 614 ± 76.4, 1,764 ± 166, 4,652 ± 300 and 17,518 ± 3,178 ng/mL attained at 0.38, 0.75, 0.50 and 0.83 h, respectively, after oral administration of Orteronel at 5, 10, 30 and 100 mg/kg as a suspension. In the dose proportional oral pharmacokinetic study, the mean t ½ by oral route was found to be ~3.5 h and bioavailability ranged between 69 and 89 %. The primary route of elimination for Orteronel is urine.
Similar content being viewed by others
References
Auchus RJ (2004) Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med 22:281–288
Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488–1490
Dreicer R, Agus DB, MacVicar GR, MacLean T, Zhang W, Stadler M (2010) Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. In: ASCO Genitourinary Cancer Symposium Proceedings, June 3–7, Chicago, IL, USA, Abstract 103
Gurav S, Police A, Zainuddin M et al (2012) Development and validation of a highly sensitive LC-MS/MS-ESI method for determination of Orteronel® (TAK-700) in rat plasma: application to a pharmacokinetic study. Bioanalysis 4:1471–1480
Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154–179
Kaku T, Hitaka T, Ojida A et al (2011) Discovery of Orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 19:6383–6399
Matsunaga N, Kaku T, Ojida A, Tasaka A (2004) Synthetic studies on (1S)-1-(6,7-dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methylpropan-1-ol as a selective C17,20-lyase inhibitor. Tetrahedron Asymmetry 15:2021–2028
Molina A, Belldegrun A (2011) Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 185:787–794
Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447–4454
Ojida A, Yamano T, Taya N, Tasaka A (2002) Highly enantioselective reformatsky reaction of ketones: chelation-assisted enantioface discrimination. Org Lett 4:3051–3054
Saad F, Akaza H, Eisenberger MA et al (2011) A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). In: ASCO Annual Meeting, June 3–7, Chicago, IL, USA, Abstract No: TPS 184
Salvador JA, Pinto RM, Silvestre SM (2013) Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. J Steroid Biochem Mol Biol 137:199–222
Taplin ME (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4:236–244
Vasaitis TS, Bruno RD, Njar VC (2011) CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 125:23–31
Conflict of interest
The authors have no conflicts of interest relevant to the ideas and/or contents of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zainuddin, M., Vinod, A.B., Gurav, S.D. et al. Preclinical assessment of Orteronel®, a CYP17A1 enzyme inhibitor in rats. Eur J Drug Metab Pharmacokinet 41, 1–7 (2016). https://doi.org/10.1007/s13318-014-0229-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-014-0229-2